 |
160 Products |  |
813 Diseases | | 160 Products |
|
1618 Trials |  |
78436 News |  |
| «12...896897898899900901902903904905906...910911» |
- AMG 579 / Amgen
Trial termination: First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia (clinicaltrials.gov) - Oct 4, 2012
P1, N=50, Terminated, Sponsor: Amgen
Recruiting --> Terminated; Amgen decision (business)
- | motesanib (AMG 706) / Takeda
Trial termination: An Open Label Treatment Extension Study of AMG 706 (clinicaltrials.gov) - Oct 4, 2012
P2, N=94, Terminated, Sponsor: Amgen
Recruiting --> Terminated; Amgen decision (business) Active, not recruiting --> Terminated; Amgen decision
- AMG 579 / Amgen
Enrollment change: First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia (clinicaltrials.gov) - Oct 4, 2012
P1, N=50, Terminated, Sponsor: Amgen
Active, not recruiting --> Terminated; Amgen decision N=66 --> 50
- methotrexate IV / Generic mfg., cytarabine / Generic mfg.
Enrollment change: Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 4, 2012
P2, N=19, Completed, Sponsor: M.D. Anderson Cancer Center
N=66 --> 50 N=45 --> 19
- || New P3 trial: High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) (clinicaltrials.gov) - Oct 4, 2012
P3, N=2000, Recruiting, Sponsor: St. Anna Kinderkrebsforschung
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer (clinicaltrials.gov) - Oct 4, 2012
P3, N=399, Completed, Sponsor: Southwest Oncology Group
N=45 --> 19 Active, not recruiting --> Completed
- Ibrance (palbociclib) / Pfizer
New P1 trial: A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia (clinicaltrials.gov) - Oct 3, 2012
P1, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Epogen (epoetin alfa) / Amgen
Enrollment change: Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=89, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Completed N=180 --> 89
- ivabradine / Generic mfg.
New P4 trial: Dig&Iva: Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure (clinicaltrials.gov) - Oct 2, 2012
P4, N=22, Completed, Sponsor: Cocco, Giuseppe, M.D.
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., bendamustine / Generic mfg.
New P2 trial: Bendamustine, Lenalidomide (Revlimid (clinicaltrials.gov) - Oct 2, 2012
P2, N=50, Recruiting, Sponsor: Cantonal Hospital of St. Gallen
- || Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen
Enrollment closed, Metastases: A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies (clinicaltrials.gov) - Oct 2, 2012
P1, N=90, Active, not recruiting, Sponsor: MedImmune LLC
N=180 --> 89 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Roche
Enrollment closed: S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=200, Active, not recruiting, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=89, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial completion: S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 2, 2012
P2, N=56, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, plerixafor / Generic mfg.
Enrollment change: Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=47, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=72 --> 47
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, plerixafor / Generic mfg.
Trial completion: Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=47, Completed, Sponsor: M.D. Anderson Cancer Center
N=72 --> 47 Active, not recruiting --> Completed
- Trial completion: Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=25, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial termination, Combination therapy, Metastases: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors (clinicaltrials.gov) - Sep 30, 2012
P1/2, N=89, Terminated, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Sponsor decision - subjects rolled over to protocol 20101116
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 30, 2012
P2, N=0, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Terminated; Sponsor decision - subjects rolled over to protocol 20101116 N=36 --> 0
- |||||||||| rilotumumab (AMG 102) / Amgen
New P3 trial, Metastases: RILOMET-1: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Sep 30, 2012
P3, N=450, Recruiting, Sponsor: Amgen
- ||||| abrilumab (AMG 181) / Amgen, AstraZeneca
New P2 trial: Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Sep 27, 2012
P2, N=252, Recruiting, Sponsor: Amgen
- Trial completion: Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes (clinicaltrials.gov) - Sep 27, 2012
P2, N=16, Completed, Sponsor: Case Comprehensive Cancer Center
N=36 --> 0 Active, not recruiting --> Completed
- ||| AMG 357 / Amgen
New P1 trial: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects (clinicaltrials.gov) - Sep 26, 2012
P1, N=58, Recruiting, Sponsor: Amgen
- ||||| abrilumab (AMG 181) / Amgen, AstraZeneca
New P2 trial: Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Sep 25, 2012
P2, N=360, Recruiting, Sponsor: Amgen
- Rituxan (rituximab) / Roche
Enrollment closed: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=63, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Epogen (epoetin alfa) / Amgen
Enrollment change: Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa (clinicaltrials.gov) - Sep 24, 2012
P4, N=3, Terminated, Sponsor: University of South Florida
Recruiting --> Active, not recruiting N=20 --> 3
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P2 trial, Metastases: A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer (clinicaltrials.gov) - Sep 24, 2012
P2, N=44, Completed, Sponsor: University of Chicago
- Trial termination, Minimal residual disease: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=3, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=20 --> 3 Active, not recruiting --> Terminated; Low accrual
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: MAINTAIN: Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice (clinicaltrials.gov) - Sep 23, 2012
P4, N=780, Completed, Sponsor: Pfizer
- Neulasta (pegfilgrastim) / Roche
New P2 trial, Metastases: Dacarbazine and Carmustine in Metastatic Melanoma (clinicaltrials.gov) - Sep 23, 2012
P2, N=35, Recruiting, Sponsor: Western Regional Medical Center
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed: PALOMA-1;TRIO-18: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=177, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Terminated; Low accrual Recruiting --> Active, not recruiting
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=145, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion: Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer (clinicaltrials.gov) - Sep 23, 2012
P2, N=45, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease (clinicaltrials.gov) - Sep 20, 2012
P3, N=358, Completed, Sponsor: Amgen
Active, not recruiting --> Completed N=540 --> 358
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Biomarker: Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=25, Recruiting, Sponsor: VU University Medical Center
- ||||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion: Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease (clinicaltrials.gov) - Sep 20, 2012
P3, N=358, Completed, Sponsor: Amgen
N=540 --> 358 Recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial termination: Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=47, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- Stivarga (regorafenib) / Bayer
Stroma: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=0, Available, Sponsor: Bayer
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
New P3 trial: Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis (clinicaltrials.gov) - Sep 19, 2012
P3, N=240, Recruiting, Sponsor: Celgene Corporation
- | Trial completion: Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=222, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Sep 19, 2012
P3, N=214, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial initiation date: Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis (clinicaltrials.gov) - Sep 18, 2012
P4, N=200, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Initiation date: Jun 2010 --> Nov 2010
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Sep 18, 2012
P4, N=20, Active, not recruiting, Sponsor: University of Maryland
Initiation date: Jun 2010 --> Nov 2010 N=40 --> 20
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients (clinicaltrials.gov) - Sep 18, 2012
P1, N=60, Completed, Sponsor: Amgen
- ||||||| Prolia (denosumab) / Amgen
Trial completion: A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates (clinicaltrials.gov) - Sep 18, 2012
P3, N=833, Completed, Sponsor: Amgen
N=40 --> 20 Active, not recruiting --> Completed
- ||||| Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment change: Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) (clinicaltrials.gov) - Sep 16, 2012
P3, N=60, Active, not recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Active, not recruiting --> Completed N=30 --> 60
- | Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment change: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon (clinicaltrials.gov) - Sep 16, 2012
P3, N=43, Completed, Sponsor: Raptor Pharmaceuticals Inc.
N=30 --> 60 N=20 --> 43
- ||||| Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment closed: Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) (clinicaltrials.gov) - Sep 16, 2012
P3, N=60, Active, not recruiting, Sponsor: Raptor Pharmaceuticals Inc.
N=20 --> 43 Recruiting --> Active, not recruiting
- || Procysbi (cysteamine bitartrate delayed release) / Amgen
Trial completion: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon (clinicaltrials.gov) - Sep 16, 2012
P3, N=43, Completed, Sponsor: Raptor Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| motesanib (AMG 706) / Takeda
Trial completion, Metastases: A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Sep 16, 2012
P2, N=184, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed